BIOGNOSYS
14.12.2021 16:02:08 CET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics” , during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
Volante Technologies launches “Vol360i” Agentic AI at the core of payments, setting a new global standard for intelligence in banking9.6.2026 15:00:00 CEST | Press release
Agents deliver configurable, confidence-based automation and predictability to financial institutions through exception handling, routing, and SLA monitoring Volante Technologies, the global leader in Payments as a Service (PaaS), today announced that its Payments Platform and PaaS operations are now powered by its “Vol360i” Agentic AI. The core upgrade unlocks autonomous and semi-autonomous collaboration to reduce manual intervention, significantly increasing straight-through processing (STP) rates to over 95%, accelerating exception resolution, and proactively managing SLA performance. Vol360i is immediately available to Volante banking and financial institution clients, with four main operating principles guiding Volante’s agentic framework to deliver a frictionless payments experience: Prevent Agents: Eliminate failures before they occur, boosting reliability and reducing customer-impacting errors. Repair Agents: Self-healing AI fixes problems in real time, allowing operators to fo
Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance9.6.2026 15:00:00 CEST | Press release
Snowflake Cortex Agents support in Boomi Agentstudioenables joint customers to govern all their agents in a single, vendor-agnostic control tower Boomi, the data activation company for AI and an Elite Snowflake partner, today announced the launch of Snowflake Cortex Agents support for Agentstudio. This new integration, powered by Snowflake, enables organizations to monitor, manage, and govern every Cortex Agent that is part of their agentic workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609131798/en/ Boomi Adds Snowflake Cortex Agents Support to Agentstudio to Enable Unified AI Agent Governance "Customers are scaling AI agents into production, and partners are bringing new solutions to market at record speed, both powered by Boomi Agentstudio,” said Steve Lucas, Chairman and CEO at Boomi. “This dual momentum reflects the unique strength of the Boomi Enterprise Platform, empowering innovation while ensuring gove
Xsolla Brings Direct-to-Consumer Commerce Expertise to Gamesforum Hamburg 2026 With Keynote and Panel Appearances9.6.2026 14:01:00 CEST | Press release
As An Exclusive Global Partner Of The Gamesforum Series, Xsolla Takes Two Stages In Hamburg, Headlined By A Keynote With AppsFlyer On Web Shop Attribution Xsolla, a global leader in video game commerce, today announced its participation in Gamesforum Hamburg 2026, taking place June 9–10, 2026, at NORD EVENT Panoramadeck in Hamburg, Germany. As an Exclusive Global Partner of the Gamesforum series, Xsolla will bring its direct-to-consumer commerce expertise to one of Europe's leading gatherings for mobile game growth and monetization, with Jane Startseva, Vice President of Business Development, EMEA, taking the stage across two sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609166526/en/ Graphic: Xsolla Xsolla's presence in Hamburg underscores its role at the center of gaming's shift toward direct-to-consumer commerce: On June 9 at 10:00 AM, Jane joined Adam Smart, Global Director of Product – Gaming at AppsFlyer,
Duetti Expands Funding Offerings for Independent Artists With Two New Programs9.6.2026 14:01:00 CEST | Press release
Master Tracks as Young as Six Months Now Eligible for Acquisition Deals; New Remix Program Expands Collaboration Opportunities Duetti Inc. (“Duetti” or the “Company”), the music company that partners with independent artists and songwriters to buy, manage, and market their catalogs, announces today a significant expansion of its funding offering. Artists can now sell their master recording tracks, or parts thereof, in as little as six months after release - substantially earlier than the company’s prior two-year threshold. Duetti is also launching its new Remix Program, which allows independent artists to create remixes, covers, and other derivative works from Duetti’s 30,000-track catalog (across both masters and compositions). In return, artists can receive upfront cash compensation, ongoing royalty % share, 0% distribution fees, and dedicated marketing support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609063445/e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom